Answers are grounded in this paper and cite their sources.
Demonstrates dose-dependent inhibition of adipocyte differentiation by HIV protease inhibitors in murine preadipocytes, suggesting a mechanism for therapy-associated lipodystrophy.
Patients with AIDS who are receiving therapy with HIV protease inhibitors have been widely reported to be afflicted with a syndrome characterized by lipodystrophy (fat redistribution favoring the accumulation of abdominal and cervical adipose tissue), hyperlipidemia, and insulin resistance. HIV protease inhibitors have been suggested to have a direct role in modulating adipocyte differentiation. To address this hypothesis, several HIV protease inhibitors were studied for their ability to either augment or inhibit the differentiation of murine 3T3-L1 preadipocytes. Dose-responsive inhibition of adipogenesis by several protease inhibitors was noted as measured by reduced triglyceride accumulation and attenuated induction of three differentiation marker genes − aP2, lipoprotein lipase, and Adipo Q. Potential mechanisms for altered adipocyte function, including direct binding to PPARγ or inhibition of PPARγ-mediated gene transcription were effectively excluded.
No takes yet. Share an insight, caveat, or question.
B. Zhang (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: